A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Durvalumab (Primary) ; Savolitinib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms SAMETA
- Sponsors AstraZeneca AB
- 23 Jul 2024 Planned End Date changed from 14 Sep 2026 to 12 Jun 2026.
- 23 Jul 2024 Planned primary completion date changed from 30 May 2025 to 30 Jun 2025.
- 07 Jun 2023 Planned primary completion date changed from 19 Sep 2025 to 30 May 2025.